Lineage Cell Therapeutics Achieves Milestone in Collaboration with Genentech and Roche

Reuters

2025/11/25

<a href="https://laohu8.com/S/LINE">Lineage</a> Cell <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Achieves Milestone in Collaboration with Genentech and Roche

Lineage Cell Therapeutics Inc. has entered into a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the development of OpRegen® (RG6501), a suspension of human allogeneic retinal pigment epithelial (RPE) cells aimed at treating geographic atrophy (GA) secondary to dry age-related macular degeneration $(AMD)$. Lineage recently announced the achievement of the first milestone under this collaboration, which is tied to manufacturing and clinical advancements in the OpRegen cell therapy program. The partnership includes potential milestone payments totaling up to $620 million and involves an exclusive global development effort currently being evaluated in a Phase 2a clinical study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2586496407"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586496407\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586496407?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 00:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586496407","market":"nz","top_or_hot":-1,"title":"Lineage Cell Therapeutics Achieves Milestone in Collaboration with Genentech and Roche","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LINE\">Lineage</a> Cell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Achieves Milestone in Collaboration with Genentech and Roche\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LCTX\">Lineage Cell Therapeutics Inc</a>. has entered into a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the development of OpRegen® (RG6501), a suspension of human allogeneic retinal pigment epithelial (RPE) cells aimed at treating geographic atrophy (GA) secondary to dry age-related macular degeneration <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a>. Lineage recently announced the achievement of the first milestone under this collaboration, which is tied to manufacturing and clinical advancements in the OpRegen cell therapy program. The partnership includes potential milestone payments totaling up to $620 million and involves an exclusive global development effort currently being evaluated in a Phase 2a clinical study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lineage Cell Therapeutics Achieves Milestone in Collaboration with Genentech and Roche</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLineage Cell Therapeutics Achieves Milestone in Collaboration with Genentech and Roche\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-25 00:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LINE\">Lineage</a> Cell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Achieves Milestone in Collaboration with Genentech and Roche\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LCTX\">Lineage Cell Therapeutics Inc</a>. has entered into a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the development of OpRegen® (RG6501), a suspension of human allogeneic retinal pigment epithelial (RPE) cells aimed at treating geographic atrophy (GA) secondary to dry age-related macular degeneration <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a>. Lineage recently announced the achievement of the first milestone under this collaboration, which is tied to manufacturing and clinical advancements in the OpRegen cell therapy program. The partnership includes potential milestone payments totaling up to $620 million and involves an exclusive global development effort currently being evaluated in a Phase 2a clinical study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LCTX","symbol_name":"Lineage Cell Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDLbqqtYz:1","article_id":"2586496407","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586496407","pubTimestamp":1764001508,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lineage Cell Therapeutics Inc. has entered into a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the development of OpRegen , a suspension of human allogeneic retinal pigment epithelial  cells aimed at treating geographic atrophy  secondary to dry age-related macular degeneration . Lineage recently announced the achievement of the first milestone under this collaboration, which is tied to manufacturing and clinical advancements in the OpRegen cell therapy program. The partnership includes potential milestone payments totaling up to $620 million and involves an exclusive global development effort currently being evaluated in a Phase 2a clinical study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LCTX":"Lineage Cell Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Lineage Cell Therapeutics与基因泰克和罗氏合作实现里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LCTX":0.9},"content_text":"Lineage Cell Therapeutics Achieves Milestone in Collaboration with Genentech and Roche\n    \n\nLineage Cell Therapeutics Inc. has entered into a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the development of OpRegen® (RG6501), a suspension of human allogeneic retinal pigment epithelial (RPE) cells aimed at treating geographic atrophy (GA) secondary to dry age-related macular degeneration $(AMD)$. Lineage recently announced the achievement of the first milestone under this collaboration, which is tied to manufacturing and clinical advancements in the OpRegen cell therapy program. The partnership includes potential milestone payments totaling up to $620 million and involves an exclusive global development effort currently being evaluated in a Phase 2a clinical study.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}